Company Reports / Shire Pharmaceuticals

COMPANY: Shire Pharmaceuticals


Total Impact Score: 726,457.21

Shire Pharmaceuticals is ranked 6th place in our index for 2015. Shire Pharmaceuticals’s drugs have a total impact score of 726,457.21. Shire Pharmaceuticals treats one disease in our model - HIV - with one total drug - Lamivudine (3TC). Shire Pharmaceuticals receives credit for one treatment against HIV - Lamivudine (3TC). This one drug averted 705,778.12 of the total DALYS for HIV, which is 27.54% of the worldwide DALYs that we estimate would have been lost due to HIV in 2015 in the absence of effective treatment. Shire Pharmaceuticals’s drug portfolio placed it 1st in terms of total averted DALYs for HIV.

Company Score Breakdown:

Key Drugs


Lamivudine (3TC) is an ARV drug recommended by the WHO in the treatment of HIV as a part of preferred first-line regimens for adults, adolescents, and children, as part of the recommended regimen for children also being treated for TB, and in cases of HBV coinfection. Major toxicity concerns include lactic acidosis and disorders of lipid metabolism. IAF Biochem first patented 3TC, changed its name to Biochem Pharma, and merged with Shire Pharmaceuticals in 2000.

Company Information

Shire Pharmaceuticals is a global pharmaceutical company, headquartered in Massachusetts and founded in 1986 by a group of entrepreneurs, specializing in the treatment of rare diseases. They are set to be acquired by Takeda Pharmaceutical by the 1st half of 2019. They focus their research and manufacturing in the areas of: hematology, neuroscience, immunology, genetic diseases, internal medicine and ophthalmics. Major products include: Adderall®, Lialda®, and Gammagard Liquid®. Shire has programs to improve access to medical care focused around hemophilia including OnePath® and Shire Cares®. Through an agreement with the World Federation of Hemophilia they provide annual donations of clotting factor, donating nearly eight million units in 2017. Shire, in collaboration with Canada’s Access to Medicine Regime, has recently allowed royalty-free access to HIV/AIDS medicines for Rwanda to improve health and save lives in the developing world. In 2017, Shire earned a revenue of $15.16 billion and employed approximately 23,000 workers in 100 countries.

Company Report PDF